InspireMD, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2013. Although the request metadata refers to 2012 Q4, this is an annual report, not a quarterly filing; the filing presents full-year comparisons with the year ended June 30, 2012.
Business context
InspireMD develops and commercializes MGuard, a stent platform with a mesh sleeve intended to reduce embolic debris during stenting. Its marketed products primarily target acute coronary syndromes and are sold internationally through distributors. The company reported no U.S.-approved products. MGuard Coronary and MGuard Prime had CE Mark approval; MGuard Carotid received CE Mark approval in March 2013, but further development was temporarily delayed pending funding.
Key financial metrics
| Metric | Year ended June 30, 2013 | Year ended June 30, 2012 |
|---|---|---|
| Revenue | $4.873 million | $5.349 million |
| Gross profit / margin | $2.590 million / 53.2% | $2.500 million / 46.7% |
| Operating loss | $15.073 million | $17.545 million |
| Net loss | $29.258 million | $17.597 million |
| Basic and diluted loss per share | $1.39 | $1.04 |
| Cash used in operating activities | $10.300 million | $8.580 million |
| Cash and cash equivalents at year-end | $14.820 million | $10.284 million |
At June 30, 2013, current assets were $18.905 million and current liabilities were $4.043 million; management reported working capital of approximately $14.9 million and a current-assets-to-current-liabilities multiple of 4.68. The company reported no convertible loan at year-end. It settled its secured convertible debentures in April 2013, paying $8.787 million in cash and issuing 2,159,574 shares and warrants for 659,091 shares.
Changes versus the prior comparable period
- Revenue fell 8.9%, primarily from lower sales volume during a transition away from certain distributors toward direct sales; price increases partly offset the decline.
- Gross profit rose 3.6% and gross margin increased 6.5 percentage points, aided in part by the absence of a prior-year $0.4 million slow-moving inventory write-off.
- Operating expenses declined to $17.663 million from $20.045 million, mainly because of lower share-based compensation in general and administrative expense. Selling and marketing expense rose 66.3% to $3.616 million.
- Net loss widened by $11.661 million. Financial expense increased to $14.177 million from $38,000, primarily due to non-recurring, largely non-cash costs associated with the debt exchange and debt-issuance-cost amortization. Management stated that excluding specified non-recurring, non-cash debt-exchange and amortization effects, net loss would have been approximately $15.8 million.
- Cash increased by $4.536 million, supported by approximately $22.6 million of net proceeds from an April 2013 public offering. Operating cash use increased year over year.
Outlook, commentary, and risks
- Management said available cash was expected to fund operations into 2015, but additional financing might be needed in 2015 depending on 2014 operating results. The company has a history of losses and negative operating cash flow.
- The U.S. pivotal trial for MGuard Coronary began enrollment in July 2013. It was planned for up to 1,114 patients, with an estimated budget of up to $13.0 million; U.S. approval was targeted for 2016. Timing and costs remain subject to clinical, regulatory, funding, and enrollment risks.
- In the 433-patient MASTER trial, MGuard improved complete ST-segment resolution versus control stents (57.8% vs. 44.7%; p=0.008) and TIMI 3 flow (91.7% vs. 82.9%; p=0.006). Major adverse cardiac events were not statistically significantly different at 30 days or six months. Management also disclosed that the trial did not show a statistically significant reduction in these events.
- Clinical development of carotid, peripheral, and drug-eluting mesh products was delayed, suspended, or dependent on additional funding. The filing notes that the Brazilian registry had enrolled only 24 of a planned 500 patients as of September 16, 2013.
- Commercial risks include strong competitors with greater resources, reliance on distributors and key customers, single-source suppliers, manufacturing scale-up and quality requirements, reimbursement uncertainty, and potential intellectual-property litigation. Three distributors accounted for 17%, 14%, and 10% of 2013 revenue, respectively.
- The filing disclosed a pending Israeli securities-law matter concerning alleged historical securities offers; the company stated it believed penalties were unlikely. It also described legal claims and provisions, including an Argentine employment claim with a recorded provision of $250,000 and potential additional loss estimated at up to $80,000.
- Management concluded disclosure controls and internal control over financial reporting were effective as of June 30, 2013. The auditor issued an unqualified opinion on the financial statements.
Important facts for investors to verify
- Whether cash burn, trial spending, and commercial performance support management’s stated runway into 2015, and what financing may be required afterward.
- U.S. pivotal-trial enrollment, funding, milestones, and results, including the distinction between improved reperfusion measures and the absence of a significant MACE reduction in MASTER.
- Revenue trends after distributor changes, customer concentration, distributor order-minimum shortfalls, and progress in direct sales channels.
- The full dilution and potential share impact of the public offering, debt settlement, warrants, and other outstanding equity awards.
- Updates to material legal matters, regulatory approvals, reimbursement access, and supply continuity for key components.